Profile data is unavailable for this security.
About the company
Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.
- Revenue in GBP (TTM)0.00
- Net income in GBP-3.33m
- Incorporated1985
- Employees5.00
- LocationOvoca Bio PLC17 Pembroke Street, UpperDUBLIN D02 AT22IrelandIRL
- Phone+353 16619819Fax+353 16619895
- Websitehttps://ovocabio.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Theravet SA | -83.67bn | -83.67bn |
| Epigenomics AG | -83.67bn | -83.67bn |
| Oxurion NV | 70.28k | -9.52m |
| Diagonal Bio AB | 1.69k | -853.84k |
| 2cureX AB | 6.40k | -1.94m |
| Ovoca Bio PLC | 0.00 | -3.33m |
| Private Rented Sector SA | 19.39k | -13.02k |
| Lidds AB | 0.00 | -1.88m |
| ATTANA AB | 377.87k | -895.24k |
| Circio Holding ASA | 8.80k | 680.15k |
